2019 Rare Disease Day: Prodia Provides Genetic Tests to Implement CSR for Indonesia Rare Disorders Community

Caption: From left to right: Commissioner of Prodia, Gunawan Prawiro; Chief of Indonesia Rare Disorders (IRD) Community, Yola Tsagia; Managing Director of PT Prodia Widyahusada Tbk, Dewi Muliaty; President Commissioner of Prodia, Andi Widjaja; and Director of Social Rehabilitation for People with Disability of Ministry of Social Affairs of the Republic of Indonesia, Rachmat Koesnadi taking picture together during Bridging Health & Social Care 2019 talk show at Prodia Tower on Thursday (14/03). Prodia gave support by conducting Chromosomal Microarray Analysis (CMA) genetic test for Indonesia Rare Disorders Community.

JAKARTA, 14 March 2019 – A rare disease is a disease suffered by a very few people out of the total population. In Southeast Asia, over 45 million people or approximately 9% of its population suffer from rare diseases. Meanwhile, specifically in Indonesia, approximately 25 million people out of the total population are patients of rare diseases, most of the diseases are caused by genetic disorders.

Celebrating the 2019 Rare Disease Day on 28 February, PT Prodia Widyahusada Tbk (ticker symbol: PRDA) conducted Chromosomal Microarray Analysis (CMA) genetic test for Indonesia Rare Disorders (IRD) Community as a form of its Corporate Social Responsibility (CSR). The genetic test as a support from Prodia was symbolically given by the Managing Director of Prodia, Dewi Muliaty, to the Chief of IRD, Yola Tsagia, at the Auditorium on the 10th Floor, Prodia Tower, Jakarta Pusat. The ceremony was also attended by the Director of Social Rehabilitation for People with Disability of Ministry of Social Affairs of the Republic of Indonesia, Rachmat Koesnadi; the President Commissioner of Prodia, Andi Widjaja; and the Commissioner of Prodia, Gunawan Prawiro, as well as Down Syndrome Community, Community of Trisomy 13 and 18, Rubella Friendly Home Community, Cerebral Palsy Community, Autism Community, Hydrocephalus Indonesia Community, Prader-Willi Syndrome Community, and Digeorge Syndrome Community.

Dewi Muliaty stated that this genetic test was given to realize Prodia’s commitment towards the communities of people with genetic disorders. “We hope that this CMA will be useful for the sufferers of rare diseases and genetic disorders. Prodia is committed to developing esoteric and genomic tests useful to support the P4 medicine service comprising the predictive, preventive, personalized, and participatory medicine,” said Dewi in her speech at Prodia Tower (14/03).   

Chromosomal Microarray Analysis (CMA) genetic test is a method used to see the changes of chromosome number and structure inside the body. CMA is able to identify big or small genetic changes on the addition or reduction of the copies (copy number variant or CNV). Small changes on the CNV are also likely to cause abnormal development. This CMA test can detect inherited chromosomal abnormalities pattern or uniparental disomy (UPD), genetic uniformity or absence of heterozygosity (AOH) as well as genetic disorders such as digeorge syndrome and autism spectrum disorder.

In addition, Prodia, together with IRD, also held a talk show employing the theme of Bridging Health & Social Care, involving genetic counselor, dr. Widya Eka Nugraha Msi. Med; family psychologist, Rahma Paramita M.Psi; and a mother of the patient of rare disease, Tri Amarnita. This talk show discussed the information about rare diseases and genetic disorders, the forms of psychological support from family for the sufferer of rare diseases or genetic disorders, and the importance of gene-based laboratory checkup for detecting genetic disorders.

Chief of IRD, Yola Tsagia, appreciated Prodia’s provision of CMA genetic test. “We would like to thank Prodia for providing us, the sufferers of rare disease, CMA genetic test. Through this event, we hope people will know more about rare diseases and the things to be done by the family whose member is a rare disease patient,” Yola stated.

Recently, Prodia also had launched Cancer Risk (CArisk) test which is a genomic test used to analyze more than 64 genes and 65 variants related to the risk of 9 types of cancer namely breast, colon or colorectal, cervical, liver, pancreatic, lung, stomach, thyroid and uterine. The other genomic risks tests that will be developed can be used to map the risk of cardiovascular disease, hypertension, diabetes, and autoimmune diseases based on genes.

Furthermore, Prodia also provides EGFR ctCDNA gene mutation test and ultrasensitive EGFR Mutation T790M to determine the treatment of lung cancer; ProHealthy Gut for intestinal health checks, ProSafe for non-invasive prenatal testing (NIPT), which is a superior test to predict the risk of down syndrome in pregnancy; and the Telomere Analysis reference to determine the biological age of an individual. Prodia is the pioneer of clinical laboratory in Indonesia that serves the latest medical tests.   

******

About PT Prodia Widyahusada Tbk.
 
Prodia Clinical Laboratory was initially established in Solo on 7 May 1973 by a group of idealist pharmacists. From the very first, Dr. Andi Widjaja, MBA along with the other founders have been committed to present the best test results with wholehearted services.

As the market leader, since 2012 Prodia has been the only laboratory and clinic in Indonesia accredited by the College of American Pathologists (CAP). It implies that the quality of the test result from Prodia’s laboratory is equal to those of international laboratories.
 
On 7 December 2016, the Indonesia Stock Exchange officially listed the initial public offering of Prodia as the 15th issuer in 2016, with the ticker symbol “PRDA”. In that corporate action, Prodia offered 187.5 million shares. Accordingly, the fund raised from the Company’s initial public offering (IPO) was Rp1.22 trillion.

Currently, Prodia has had the service network that incorporates 294 outlets, consisting of 146 clinical laboratories across 34 provinces and 123 cities in Indonesia, some of them are Prodia Health Care (PHC) - a personalized medicine-based wellness clinic – and specialty clinics, including Prodia Children’s Health Center (PCHC), Prodia Women’s Health Center (PWHC) and Prodia Senior Health Center (PSHC).     

Prodia has launched Prodia Contact on 1-500-830 and an online personal assistant Ask Prodia (TANIA). TANIA can be accessed by anyone, especially Prodia customers, anytime and anywhere online, through LINE: @prodia.id, Telegram: @prodia.id, Facebook Messenger: @prodia.id, and Prodia Website: www.prodia.co.id .

For further information, please contact:
Marina Eka Amalia                                                                                           
Legal Head & Corporate Secretary
PT Prodia Widyahusada Tbk.                
Ph.          :   +62-21 3144182 ext 3816                
E-mail    :   corporate.secretary@prodia.co.id